Neurocrine Biosciences Inc (NBIX) EBT Margin (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported EBT Margin for 16 consecutive years, with 30.3% the latest figure, recorded in Q1 2026.

• EBT Margin for Q1 2026 came in at 30.3%, up 2773.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 30.22% (up 1089.0% YoY), and the FY2025 annual result was 24.66%, up 403.0% from the prior year.
• EBT Margin was 30.3% for Q1 2026 at Neurocrine Biosciences, up from 29.72% in the prior quarter.
• Over five years, EBT Margin peaked at 38.47% in Q4 2023 and troughed at 116.5% in Q2 2022.
• Average EBT Margin over 5 years is 12.39%, with a median of 25.24% recorded in 2022.
• Year-over-year, EBT Margin plunged 13640 bps in 2022 and soared 14336 bps in 2023.
• Over 5 years, EBT Margin stood at 28.62% in 2022, then soared by 34 bps to 38.47% in 2023, then slumped by 33 bps to 25.9% in 2024, then gained by 15 bps to 29.72% in 2025, then gained by 2 bps to 30.3% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 30.3% in Q1 2026, 29.72% in Q4 2025, and 36.71% in Q3 2025.